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Abstract
The tendency for the Human Immunodeficiency Virus (HIV) to proliferate and mutate it’s
trimeric envelop (Env), is one of the reasons why it’s a challenge for an antibody-based vaccine to
be developed. Glycoprotein 160 (gp160,) which consists of glycoprotein 120 (gp120) and
glycoprotein 41 (gp41), is the main focus for a research vaccine design. Gp120 consists of an outer
membrane, inner membrane and bridging sheet. The protein is trimeric, and non-covalently binds
to gp41. The outer domain is where the neutralizing antibody bind, such as 2G12, immunoglobulin
G1b12, and anti-V3 antibodies. V3 stands for the Variable loop 3, gp120 has 5 variable loops that
contribute to the binding of the envelope to the CD4 binding sites. These loops are important in
immunogenicity and the binding of monoclonal neutralizing antibodies (mNAb). The V3 loop has
a conserved structural element despite its variation sequence, and due to this conserved element,
the anti-V3 antibodies can recognize and neutralize the virus. The anti-V3 antibodies can tolerate
the sequence changes in the V3 loop in certain strains of the virus and at a certain stage of infection
in patients, but this is still controversial. This paper will look at the challenges in developing body
neutralizing antibodies, and the potency for anti-V3 mature antibody to neutralize and decrease
the viral load during infection. It will also cover recent and future vaccine trials using variable
loops to directly neutralize viral fusion.

Introduction
Human immunodeficiency virus (HIV) was discovered in 1983 by researchers at the
Pasteur institution in France. Since the epidemic began approximately 75 million people have
been infected worldwide, 32 million people have died of the infection, and 37.9 million people
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are currently living with HIV ( CDC, 2019). Since then, researchers have been able to categorize
the virus genomic structure as part of the retrovirus family and identify certain characteristics of
the virus. HIV is a single-stranded positive RNA, Diploid, containing highly mutagenic
glycoproteins, reverse transcriptase (RT) which has a no proof-reading function, integrase (IN),
and protease. Only one major vaccine trial that was somewhat successful, with efficacy at
preventing infection in approximately 30% of vaccinated individuals. Despite the low efficacy,
this trial was a major development in the scientific community, many scientific journals were
published based on the outcomes of RV144 vaccine success.
The error-prone reverse transcriptase is one of the major contributing factors to the
persistence of the infection, which makes the development of vaccine for the virus exceptionally
hard. HIV’s viral RNA integrates into the host cell chromosome and enters the germline through
vertical transmission. The RT can induce a high mutation rate in the variable domains of gp120,
which is the binding site for the CD4 T cells and other antigen-presenting cells.
Gp120 trimeric structure contains multiple variable loops that are involved in the
fusion of its envelope with the host's cell membrane. These variable loops are important for body
neutralizing antibodies that target gp120. Certain variable loops, if deleted will cause the virus to
be susceptible to neuralization but still fuses with the cell membrane, while other variable loop (
aka variable loop 3) if neutralized the virus will not fuses with the host’s cell transmembrane
Variable loop neutralizing antibodies' potency and efficacy in decreasing viral load
depends on the breadth of the antibody. Breadth is important for neutralizing antibodies to
recognize its target epitope and neutralize it, the higher the breadth of the antibody the more
efficient it is at neutralizing. Researchers were able to increase the potency and the breadth of
these antibodies causing them to become polyreactive, where the antibody had low affinity and
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became reactive to a variety of unrelated antigens. This polyreactivity, what makes it difficult to
engineer a neutralizing antibody that can recognize and specifically bind it’s target antigen.
Variable loop 3 structure is variable but has a conserved region if neutralize the viral
fusion will be inhibited. The challenges that come with engineering a neutralizing antibody for
variable loop 3 is the V1/V2 masks V3 loop, preventing it from being recognized and
neutralized. N-glycosylation of V3 can also resist neutralizing antibodies. We will cover recent
research regarding the potency and breadth of different neutralizing antibodies, as well as recent
vaccine trials and past trials that show promising results for future research in vaccine design.
The Variable loops
Multiple regions within the gp120 glycoprotein are involved in the receptor bindings of
the virus, these include the Five variable loops. Variable loop 1, is involved in the syncytium
formation of the virus forming a multi-nucleated enlarged cell. The loop is a site for potent
neutralizing monoclonal antibodies, there is still much to learn about the loop. The virus is
susceptible to neutralizing antibodies upon the deletion of its variable loop 2, but the deletion of
V1V2 does not inhibit the virus ability to replicate, the envelope still functions (Saunders,2005)
Variable loop 3, the amino acids of this loop are highly variable, Clade C virus contains a
conserved sequence on its V3 crown. The loop is imbedded deep, with limited breadth, despite
its strong immunogenicity and its ability to induce monoclonal neutralizing antibody it’s very
difficult to induce these antibodies due to its limited accessibility. Variable loop 4 (V4) and
Variable loop 5 (V5), are poorly defined. V4/V5 are both involved in neutralization escape, they
do go through variations during early infection, but they are not a good target for an antibodybased vaccine.
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Gp120 fusion and Variable Loop 3 structure/interaction with Cell’s Co-receptors
The role of the V3 loop is very essential for coreceptor binding (CCR5 or CXR4), these
coreceptors are important for the fusion and the entry of the virus, they interact with the loop
through hydrogen binding and occur on the N-terminus of the coreceptor and the extracellular
loop, as shown in figure 1. The binding of the coreceptor on the N-terminal usually occurs
around the core and the base of the V3 loop. The loop consists of approximately 39 amino acids,
it acts as a molecular hook for the coreceptor
and it can alternate certain subunits within the
viral spike (Huang,2005). The loop can subdivide into three regions; the Conserved base,
where the core's integral portion; flexible stem,

Figure 1. Schematic model of the gp120 as it

extend from the core, Beta-hairpin tip. The way

binds to the cell’s coreceptors and CD4 binding

the loop differentiates between the coreceptor is

sites. A) once gp120 bind it brings the V3 loop

through their charge. The loop will bind to

tip closer to the cell membrane. B) closer

CXCR4 if their 11th or the 25th position is

representation of the V3 loop as it binds to N

positively charged (Huang,2005). Once the

terminus of the CCR5 coreceptor ( Huang,

gp120 binds to CD4 a bridging sheet is formed.

2005).

The variable loop is close enough to the
coreceptor for tethering and exposure of the hydrophobic gp41 region for fusion peptide located
on the host’s membrane.
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Figure 2. Overview of HIV fusion. CD4bs of gp120 initiate it’s binding to the
CD4 transmembrane protein. Next the V3 binds to the coreceptor and bringing
gp41 hydrophobic region closer to the fusion peptide. Six helix bundle is formed
creating a fusion pore (Huang,2005).
A six helical bundle is formed when the amino-terminal region and carboxyl-terminal
region are brought closer together forming the bundle and a fusion pore, as shown in figure 2.
Where V3 binds to the coreceoper and bringing the fusoin protein closer to gp41. Once the
membrane fusion pore is formed and the virus is fused, it will release its viral content into the
host’s cytosol (Huang,2005).

The Development of Broadly neutralizing antibodies
Neutralizing antibodies(bNAbs) is the major focus for HIV vaccine development.
Individuals react differently to the HIV infection. Some might develop extremely broad and
potent neutralizing antibodies while others might not. These neutralizing antibodies have a high
level of somatic hypermutation, and their long/short antigen-binding loops can be challenging in
the development of the vaccine (Landais, 2018). These antibodies can target multiple sites on the
HIV-1 envelope, the Variable loops, membrane-proximal external region (MPER) and the CD4
binding sites. Different regions on the envelope can react and bind differently to these antibodies,
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some might require a long CDRH3 to penetrate the glycan at the apex of the trimer, while others
might require the short loop to avoid steric hindrance (Landais,2018).
The reason why antibodies can recognize multiple variable epitopes is due to their
somatic hypermutation, but many of these mutations are neutral with no breadth (breadth, is
important for antibodies to recognize their target epitope). Scientists were able to engineer a
body neutralizing antibody to achieve enhanced breadth and potency, but this usually resulted in
an enhanced polyreactive (Landais,2018) which posed a challenge to vaccine development.
The development of these antibodies depends on a feedback loop, where the increase in
the diversity of the envelope leads to an increase in the diversity of the antibody’s response, this
will result in an exposed bNAb with multiple related antigens over multiple escape pathways.
This process can aid in vaccine design through the diversification of the
envelope that leads to identifying the breadth of the antibodies. The
overall purpose of a body neutralizing antibodies is to neutralize viral
effectivity from fusion with the host’s transmembrane (Landais,2018).
Challenges of V3 neutralizing antibodies
V1/V2 masking V3 loop
Figure 3. This is a graph that
Variable loops of the gp120 play an important role in antibody
measure viral activity when
recognition and epitope masking. V1/V2 mask the V3 loop, it has
variable loop 1 and 2 are
been proven that the deletion of the V1/V2 loop would enhance the
mutated and neutralized by
neutralization of the virus by the nAbs. The study was done at the
mature antibody D19 and
National Institute of Allergy and Infectious Diseases, National
2182 (Liu, 2011).
Institutes of Health, Bethesda ( Liu,2011). Where they investigated
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the interaction between two monoclonal antibodies that are subject to mask trimer envelope of
gp120. They also looked at whether the masking was on the same protomer or adjacent
protomer. They used a firefly luciferase gene, that is used to encodes oxidizing enzymes and a
fluorescent measurement. This genome is highly used in HIV neutralization and epitope
masking.
The neutralizing antibodies were obtained from individuals who were infected with clade
A of the virus, mAb 2182 which binds to V3 loop peptide. 2182 competes with 447-52D other
neutralizing antibodies that bind to the tip of the V3 loop. They deleted the V1V2 region and as
shown in Figure 3 the deletion resulted in a drastic decrease in the survival of the virus in both
mAb2182 neutralizing antibody and the D19 another neutralizing antibody that is generated with
immunization with clade B (Liu,2011).
What’s different in the clade B is that the inhibition was plateaued at approximately
between 63% and 80% this indicates that the V1/V2 loop might not be the only one that is
masking the epitope region (Liu,2011). GPGR which is a tetra G protein-peptide varies from
virus to virus is found at the V3 tip, it has also been proven that mutation in that region will
abolish the mAB D19 antibody sensitivity but also preserver the overall fusion of the virus to the
cell.

N-glycosylation of gp120 and V3 loop causes the resistance of the neutralizing antibodies
(McCaffrey, 2004)
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Glycosylation limits the binding of antibodies to their
viral epitopes. The genetic drift of the virus cause changes in
glycosylation pattern. HIV uses glycan as a shield to protect
itself from being recognized by neutralizing antibodies, while
still maintaining the ability to recognize and interact with the
Figure 4. Replication Kinetics in

CD4 binding site. Individuals glycans play different roles in
protecting the virus from neutralization. The elimination of the Nlinked glycosylation on the amino-terminal and carboxyl of the
V3 loop (most HIV strains V3 loops contain single glycosylation

human PBMC. Open boxes mutant
viruses, while solid boxes are the
parental SF162 ( McCaffrey, 2004).

site), can silent coreceptor usage and the susceptibility for antibodies to mediate neutralization
(McCaffrey, 2004).
To examine if the elimination of glycosylation from the viral envelope does affect the
phenotype. SF162 and HIV type-1 strain is being used to determine the viral load in
human peripheral blood mononuclear cells (PBMC) after the elimination of the N-glycosylation
in variable loops (McCaffrey, 2004). One thing to keep
in mind is certain positions of glycan can impact
replication while other residues if deleted the virus can
still replicate. Shown in figure 4, GM 299 is a V3
mutated form of the virus, compared to the parental
SF162 strain.
The viral load of the mutant V3 significantly

Figure 5. bar graph measure the relative light

decreased compared to the parent SF162. This shows the

unites of efficiency of different mutant viruses

importance of V3 in viral infectivity(McCaffrey, 2004).

entering host’ cells when different viral
variable loops are mutated.
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SF162 is unable to enter the cell without V3 binding to Coreceptor, to determine the inability for
the virus to enter the host’s cell is due to the inhibition of the V3 loop glycosylation and not to
the fewer envelope molecules in the GM299 virions (McCaffrey, 2004). An engineered virus that
express either parental or the mutant SF162 envelope protein infected U87 human astroglioma
cell line, this cell line expresses multiple coreceptors. The Virus is luciferase reporter capable of
a single round of replication to either express the parental strain or the mutated strain. As shown
in the bar graph below in Figure 5, except for the V3 mutant almost every other mutant the virus
was still able to replicate and infect the U87 cell (McCaffrey, 2004).
While the V3 mutant GM299 the virus did not enter the target cell and the relative target
units were significantly low compared to the parental SF162 control. This again, evidence that
V3 loop glycan has an important role in ensuring the viral entry into the host’s cell.
To determine if glycosylation can protect the viral envelope from neutralizing
antibodies, a neutralization assay was performed where infectious doses were mixed with diluted
Mature Neutralizing antibodies (MAbs) and PBMC was added. They were mixed in a different
mutated forms of the virus at mutliple
Table 1. IC90 and IC80 concentrations of Mab that
inhibited infection of the virus. The bold indicated that
it increased the susceptibility to neutralizing compared
to control SF162 (McCaffrey, 2004).

variable loops. As shown in table 1,
Variable loop 3 had signficant value as indicated in bold, where the susceptiblity to neutralize
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compare to the parent strain SF162 is greater. It had p value of <.08 indicates a signficant
increase in neutralization, due to the V3 mutated form.

Recent Neutralizing Antibodies targeting V3 Loop
10A3/10A37
The Apex crown of the V3 loop is a great HIV vaccine target design. The study which
was published by the Department of Biochemistry and Molecular Pharmacology, NYU and
Biomedical Sciences at Iowa State University ( Ruimin Pan,2017) presented a crystal structure of
two neutralizing V3 mature Rabbit antibodies 10A3 and 10A37. These neutralizing antibodies
were capable to neutralize the V3 crown region of the HIV-1 strain, they acquired different
neutralizing capabilities. Antibody 10A3 binds to the V3 crown and stem region, in a similar
fashion to human neutralizing antibodies. What differentiates the 10A3 and the 10A37, is the
epitope region where 10A37 binds, it exists as a helical turn as shown in figure 7. This turn
seems to increase the breadth and the potency of 10A37, which seems to be a potential vaccine
study. The Rabbit neutralizing antibodies they presented were very similar to the human
neutralizing antibodies, this makes the rabbit be an excellent animal model for future vaccine
candidates.
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The binding mode of these antibodies are very similar to human’s V3 specific mature
antibodies derived from IGHV3 germline as shown in figure 6. Where the darker the color, the
higher the antibody antigens contact area.
Figure 6. Comparison of the V3 epitopes of
rabbit and human MAbs. Plot showing the
distribution and number of contacts formed with
the V3 loop by different MAbs (Ruimin
Pan,2017).

Despite the low amino acids sequence similarity to human antibody germ line, rabbit
model can still serve as a useful animal model for future vaccine development.

Figure 7. Structure of Fab 10A37 in complex with V3. (A and
B) Ribbon representations of the Fab 10A37 in complex with
V3(C) The antigen binding site of 10A37 with the CDR loops.
(D) Electrostatic potential surface of the antigen binding site of
10A37. (Ruimin Pan,2017)

The breadth and Potency of the Anti-V3 Loop neutralizing antibodies (Hioe,2010)
The conserved element of V3 can bind the host’s co-receptor and fuses, despite its
variability. Seven different pseudoviruses of HIV-1 strain were tested against anti-V3
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neutralizing antibody 2191 on different target cells lines. This demonstrated the ability that an
anti-V3-mAb was capable of neutralizing around 42% of these pseudoviruses (Hioe,2010). To
determine the potency of the antibodies, an inhibitory concentration (lC50) and the measurement
of the titration curve with its slope and area under the curve were calculated. Using two different
target cell lines the U87 and the TZM.bl cell line that expressed CD4, CCR5, and CXCR4 on its
surface (Hioe,2010). They then were treated with 50ug/ml of diluted mAbs. The luciferase
activity was measured after 72 hours of incubation. To measure the titration curve a polynomial
regression model was used to best fit the curve. The IC50 value represents the mature antibodies
concentration which corresponds with 50% of the neutralization in the titration curve. The area
under the curve represents the average neutralization within the concentration range (Hioe,2010).
Now, comparing the Area under the curve and the IC50 values to identify the
neutralization activity of the anti-V3 mAbs, as shown
in Figure 8 the neutralization curve of the seven
pseudoviruses, neutralized by the mAb2191 using
U87 as target cell were measured. Significant values
were denoted with * after the 50 percent
neutralization dash line. The confidence level of

Figure 8. Neutralization curves of the

neutralization was at a p-value of <.001(calculated by

anti V3 mature antibody 2191 against 9

comparing the area under the curve value with negative

of the pseudoviruses, as well as their

control and the titration curve slope). The curve was

IC50 and their Area under the curve, are

representative against a negative control pseudovirus an

shown to the right The confidence level

MLV and a positive control SF162, as shown in the curve

of p<.001 which is considered significant

B-011, B-034, B029, A-015, and B-016 were positive,

and is denoted with * (Hioe,2010).
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while the neutralization curves against C-026, D-030, and aMLV are negative and not significant
(Hioe,2010).
These polyclonal antibodies cross-react and neutralize the conserved element of the V3
loop. The structural element of the loop has three regions; base attached to the gp120, flexible
stem, and a crown where the anti-V3 mAbs recognizes the epitopes. The crown has a conserved
features GPG motif, which is located at the tip of the crown in a b-hairpin structure, the mature
antibody 447 interacts with this motif in a hydrophobic interaction. The V3 N-terminal will flank
the GPG turn rendering the effect of the 447 antibodies. The polar interaction with the side
chains in the GPGR motif restricts the activity of the mAb447 (Hioe,2010).
The variability in V3 is restricted at the hydrophilic region of the V3 loop b-hairpin.
Regardless of the variable region of the loop, the
constant conserved region is what the co-receptor
manly needs to participate in binding. The breadth
and potency of the anti-V3 mAbs are not that
different from other neutralizing antibodies like
b12 and 2G12 which has an IC50 value of 35%
and 42% against the U87 assay (Hioe,2010). The

Figure 9. Neutralization curves of different

polyclonal activity of the neutralizing activity against

anti-V3 mature antibodies against different

the V3 loop or the binding site for CD 4 has greater

HIV pseudo viruses, where U87 is the target

breadth than any singly mature antibody (Hioe,2010).

cell line. The Seven antibodies were, 2191,

The neutralizing ability of seven anti-V3

2219, 2557, 2558, 3074, 3869, and 447. Mab

mature antibodies and the 860 control against the

860 is the positive control while the aMLV

represented pseudoviruses carrying different Env,

Env is a negative control (Hioe, 2010).
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were observed in figure 9. 100% of antibodies neutralized the positive control SF162 and in all
of the trials the antibodies were dose-dependent. During the IC 50 value calculation, it was
shown that 32% of the viruses were neutralized by more than one anti -V3 mature antibodies at
50 mg/ml (Hioe,2010).
Also shown, each of these antibodies displayed different patterns of neutralization mAbs
2191 was found to has the highest proportions against pseudovirus and it was observed in both
target cell U87 and TZM.bl. approximately 42 % of viruses were significantly neutralized by
mAbs 2191 (Hioe,2010). As for the other anti-V3 mAbs, they were also effective in neutralizing
28-36% of the pseudoviruses and they were statistically significant. This show that anti-V3
neutralizing antibodies are capable to mediate neutralization against HIV-1 (Hioe,2010).

Vaccine Trials
RV144 Trial Phase III
The United State HIV research military research unit head the investigation of the RV144
Thai trials (Rerks-Ngarm, 2009), and on the 24th of September 2009 the results were published.
This research yielded a P value of 0.04 and vaccine efficacy (VE) of 30%. This value represents
how efficient the virus was at preventing the likely of the vaccinated individual to be infected
with HIV. The trial had 56,000 people volunteers, out of the 56,000 only 16,000 were
vaccinated. Half were placebo and the other half were vaccinated. Primary goal was to prevent
further spread of HIV infection, and to decrease the viral load of infected individuals.
These trials took place in North America, Bangkok, and Thailand where they evaluated
the efficacy of the gp120 envelope protein-based vaccine by using prim-boost of ALVAC and
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AIDSVAX. ALVAC‐HIV (vCP1521) is genetically engineered recombinant canarypox version
of HIV genes (env, gag, and pol) linked to transmembrane 3 anchoring portion of gp41.
AIDSVAX, is a genetically engineered gp120 boost. Figure 10 shows that the results from the
trials in the America and Bangkok was ineffective but the trails in Thailand had an estimated VE
of 31% and P value of 0.04 (Peter ,2011). “These results show that development of a safe and
effective preventive HIV vaccine is possible,” said Colonel Nelson Michael, Director, Division
of Retrovirology, Walter Reed Army Institute of Research and 99Director, U.S. Military HIV
Research Program (MHRP).

Figure 10. The vaccine trials took place at Thailand, North America, Bangkok, and Americas. The HIV
risk group were the general population who were mostly at heterosexual risk 61%. Men having sex with
other Men (MSM)and women ;94%. Men injection drug users were 93%. The Thailand trial had 2-sided
P value of 0.04 compared to the rest of the countries where their P value was between 0.05 (Americas)
and 0.99 Bangkok (Peter ,2011).
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The vaccine was administered at 0 week, 4 weeks, 12 weeks, and 24weeks. A booster
vaccine was given at each of the four visits, the individuals were monitored under Division of
Acquired Immunodeficiency Syndrome of the National Institute of Allergy and Infectious
Diseases (DAIDS). Subjects reported local and systemic vaccine reaction. Serious adverse
reactions were reported and graded on a scale used for rating
adverse events associated with vaccines.
Figure 11. Of the ntention-to- treat analysis group (A) all
vaccinated individuals, VE of 26.4%. Per-protocol
(B)particpanets who were eligbale to containue further
tirals, VEof 26.2%. Modified intention-to-treat (C)
excluded those who were tested positive after screeening
but before vaccination, VE of 31% (Rerks-Ngarm, 2009).

The results of Figure11 had the intention-to- treat analysis group, they involved all those
who were picked for vaccination and they had a vaccine efficacy of 26.4%. In the per-protocol
analysis involved particpanets who were eligbale to containue further tirals, they had a vaccine
efficay of 26.2%, as for the modified intention-to-treat analysis involved every particpant
excluding those who were tested positive after screeening but before vaccination, they had
vaccine efficacy of 31%. Third grpah of figure 11 (Rerks-Ngarm, 2009) was the most relevant of
90

this study, that group was 31% more likely to be protected against the virus than the intention to
treat analysis group and the per protocol analysis group. This trial identfied the correlation
between IgG antibody binding to the variable loops of HIV Env decreased risk of transmission,
and plasma IgA to Env decreased vaccine efficacy.
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Another study was done in 2012 and developed by the Pox-Protein Public Private
Partnership. The vaccine efficacy results will be out in 2020. HVTN702 2b/3 phase trial was a
build on the RV144 trial. The trial test the subtype C
prime-boost vaccine efficacy in South Africa. They
have a threshold requirement for advancement; at what
magnitude did gp120 Env binds to the antibodies,
prevalence of specific V1V2-directed binding
antibodies, and Env-specific CD4 T-cell binding

Figure 12. The timeline for HVTN HIV

(Russell,2016).

vaccine trial. Protocol review, regulatory
review, enrollment and follow up which end in
2020.

Future course of the current partially effective vaccine
in hand (Phillips,2014)
A calculated study was done in Southern Africa (Phillips,2014) to measure the effect of
antiretroviral therapy and the partially effective vaccine in hand (developed in the RV 144 trial)
was measured over the next 45 years. The vaccine with a 30% efficacy rate at preventing HIV
infection projected 67% lower HIV incidence in 2060. The vaccine will also prevent an 8%
reduction in death rate in the next 45 years, this was calculated using multivariable uncertainty
analysis.
The study was an individual-based model to investigate the impact of prophylactic
vaccines in developing country settings. This projected 67% decline in future infection can
protect the population in a herd immunity form. The study also predicted if a vaccine had a 50%
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but no effect on the viral load, will not have much impact on prevention compared to no vaccine
(Phillips,2014).
The number of HIV cases been lower in the past decade due to Antiviral medication and
educational awareness in the different regions around the world. Therefore despite the low
efficacy the RV144 prevented infection, it can prevent 8% of future death tolls.
Conclusion
Although researchers have not yet developed a vaccine for HIV, the achievement that
been accomplished in learning about the virus is remarkable. Variable loops of gp120 are
essential for coreceptor binding (CCR5 or CXR4), these loops interact with the host cell through
hydrogen bonding on the N-terminus of the coreceptor. The loops will sub-divide and bind to the
coreceptor, where a bridging sheet will form causing the tethering and exposure of the
hydrophobic gp41 region. what researchers were able to discover, is the inhibition of the variable
loops through neutralizing antibodies will neutralize the virus and decrease in viral load.
The development of these neutralizing antibodies can be a challenge, they have a high
level of somatic hypermutation and different breadth levels. Engineering these antibodies to
increase their breadth level can lead to polyreactivity where the antibody becomes reactive with
multiple antigens at once. Variable loop 3 is a good target to completely neutralize the virus
despite its variability, its crown region contains a constant and conserved region that if neutralize
viral fusion will be inhibited. N-glycosylation and the V1/V2 can prevent the recognition of the
V3 loop by anti-V3 mAbs.
Variable loop 3 is masked by variable loop 1 and 2, as shown in the previous study that
was done by the national institute of allergy and infectious diseases. They obtained mature
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antibody 2182 from an infected individual with clade A, which binds to V3 loop peptide. The
V1V2 loop was deleted, resulted in a drastic decrease in the survival of the virus in both the mAb
2182 neutralizing antibody and the D19 antibody ( another neutralizing antibody).
N-glycosylation of gp120 and V3 loop causes the resistance of neutralizing antibodies.
The mutated form of N-glycosylation did indeed decrease significantly compared to the nonmutated form. The mutation of the glycosylation resulted in a more efficient way to neutralize
the V3 loop as shown in Table 1 where the IC90 and the IC80 showed significant p value of
<.08. GM299 is the V3 glycosylation mutant form, which is important for the survival of the
virus and its neutralization, and it’s mutation increase it’s neutralization by V3 nAb.
In the past decades, multiple neutralizing antibodies were discovered that neutralizes the
V3 loop. A study was done at NYU and ISU found two mature Rabbit antibodies 10A3 and
10A37 that neutralized aV3 loop, specifically the crown of the loop region
308HIGPGRAFYTTGEI323, these antibodies had different properties from one another, 10A37
can neutralize better than 10A3 due to its structural properties. They analyzed the Fab/peptide
structure of these anti V3 neutralizing antibodies and defined their properties at the atomic level.
They are very similar in structure except for the 10A37 target the C- terminal end of the
V3 crown, and is slightly complex due to its hairpin structure, this structure seems to play a role
in the potency of the antibody. The main take away of the study was to compare these
neutralizing antibody capabilities to neutralize the V3 loop compare to human neutralizing
antibodies. The Rabbit antibodies were very similar to human antibodies which make them a
good animal model for further vaccine design.
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To further investigate the importance of the Anti-V3 mature antibodies and their
capabilities in neutralizing the fusion of the viral envelope. A study was conducted to test nine
more neutralizing antibodies against the V3 loop, some of those antibodies had different
neutralizing capabilities. mAb 2191 had the highest potency than the other neutralizing
antibodies. The IC50 and the area under the curve were statistically significant with a p value of
<.08 The neutralization efficiency of the strain increased due to the mutation in the V3 loop.
The final take away of this paper is to realize the importance of mature neutralizing
antibodies and their role in neutralizing the viral envelop from being fused with host’ cells.
Multiple studies were able to provide evidence of these antibodies to neutralize HIV strains.
There are still challenges that face research in designing antibodies that can match the everchanging structural envelope of HIV. Anti-V3 mature antibodies that can neutralize variable loop
3, targeting V3 is a promising vaccine research design.
These mAbs showed great potency and breadth in inhibiting the fusion of the viral
envelope with the host’s cell. Despite the immunogenicity of the V3, there come multiple
challenges that prevent it from being recognized by Anti-V3 mAbs, including V1/V2 masking
and N-glycosylation.
RV144 was a vaccine trial that was directed towards the V1/V2 region of gp120, where it
showed some protective measures against the virus. It had 30% preventable efficacy against the
transmission of HIV-1 strain. Variable loops regions are important to constitute in the process of
viral integration into the host’s cell. Despite the capabilities of anti V1/V2 neutralizing
antibodies to prevent infection in 30% of the population. For future vaccine research design,
focusing on variable loop 3 antibodies and improving their potency and their breadth to
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neutralize viral fusion, without compromising them to become polyreactive might show better
vaccine efficacy.

24

Acknowledgment
Dr. Joan Cunnick professor-In-Charge of Microbiology Program at Iowa State University
Dr. Wang, Xiuqing, professor in biology and microbiology at South Dakota State University
Dr. Greg Heiberger Assistant Professor Biology & Microbiology at South Dakota State University

25

References
1- HIV/AIDS. (2019, August 19). Retrieved from https://www.who.int/gho/hiv/en/.
2- Peter B. Gilbert,1-2 James 0. Berger.. Victor G. DeGruttola8. Statistical Interpretation of
the RV144 HIV Vaccine Efficacy Trial in Thailand: A Case Study for Statistical Issues in
Efficacy. ( 2011, April 1). Retrieved from:
https://www.nejm.org/doi/suppl/10.1056/NEJMoa0908492/suppl_file/nejm_rerksngarm_2209sa1.pdf
3- Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R.,
… Kim, J. H. (2009). Vaccination with ALVAC and AIDSVAX to Prevent HIV-1
Infection in Thailand. New England Journal of Medicine, 361(23), 2209–2220. doi:
10.1056/nejmoa0908492

4- Rolland, M., & Edlefsen, P. T. (n.d.). Increased HIV-1 vaccine efficacy against viruses
with genetic signatures in Env-V2. doi: 10.3897/bdj.4.e7720.figure2f
5- German Advisory Committee Blood (Arbeitskreis Blut). (2016). Human
Immunodeficiency Virus (HIV). Retrieved from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924471/pdf/tmh-0043-0203.pdf

6- Ruimin Pan,a Yali Qin,b Marisa Banasik,b William Lees,c Adrian J. Shepherd,c Michael
W. Cho,b Xiang-Peng Konga. (2017). Increased Epitope Complexity Correlated with
Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of
Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120. Retireved
from:
https://www.ncbi.nlm.nih.gov/pubmed/29343576file:///C:/Users/Riham/Documents/e018
94-17.pdf
7- Catarina E. Hioe, Rajnish Kumar. (2018). Modulation of Antibody Responses to the
V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines. Retrieved
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212562/

8- Penny L. Moore, Elin S. Gray.(2011). Potent and Broad Neutralization of HIV-1 Subtype
C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2

26

Loop. Retrieved from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067856/?report=reader
9- Mangala Rao, Kristina K. Peachman, [...], and Venigalla B. Rao. (2013).HIV-1 Variable
Loop 2 and its Importance in HIV-1 Infection and Vaccine Development. Retrieved
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086350/
10- von Bredow B, Andrabi R, Grunst M, Grandea AG 3rd, Le K, Song G, Berndsen
ZT, Porter K, Pallesen J, Ward AB, Burton DR, Evans DT. (2019). Differences in the
Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the
SIVsmm/mac Envelope Glycoprotein Uncouple Antibody-Dependent Cellular
Cytotoxicity from Neutralization.Retrived from:
https://www.ncbi.nlm.nih.gov/pubmed/31266872

11- Shang-Rung Wu, Robin Loving, Birgitta Lindqvist, Hans Hebert, Philip J. B. Koeck,
Mathilda Sjdberg, and Henrik Garoff.(2010). Single-particle cryoelectron microscopy
analysis reveals the HIV-1 spike as a tripod structure. Retrieved from:
file:///C:/Users/Riham/Downloads/HIV%20article%2014.pdf
12- Haoqing Wanga, Alexander A. Cohena, Rachel P. Galimidia, Harry B. Gristicka, Grant J.
Jensena,b, and Pamela J. Bjorkmana,1 (2016). Cryo-EM structure of a CD4-bound open
HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop.
Retrieved from: file:///C:/Users/Riham/Downloads/HIV%20article%207.pdf
13- Russell ND, Marovich MA, Pox-Protein Public Private Partnership program and
upcoming HIV vaccine efficacy trials. Current Opinion in HIV and AIDS. 2016
November 6; volume 11.

14- Maxime Moulard, Sanjay K. Phogatt, Yuuei Shut, Aran F. La Mei-Yun Zhang, Igor A.
Sidorov, Christopher C. Broder, James Dennis R. Burton, and Dimiter S. Dimitr. (2001).
Broadly cross-reactive HIV-1- neutralizing human monoclonal Fab selected for binding
to gp120-CD4-CCR5 complexes. Retrieved from:
file:///C:/Users/Riham/Downloads/HIV%20article%2013.pdf
15- Daniela Fera3, Aaron G. Schmidt3, Barton F. Haynes , Feng Gao , Hua-Xin Liao ,
Thomas B. Keplerc, and Stephen C. Harrison (2014). Affinity maturation in an HIV
broadly neutralizing B-cell lineage through reorientation of variable domains. Retrieved
from: file:///C:/Users/Riham/Downloads/HIV%20article%2012.pdf

27

16- Hui Lia, Shuyi Wanga, Rui Konga, Wenge Dinga, Fang-Hua Leea, Zahra Parkera,
Eunlim Kima, Gerald H. Learna, Paul Hahna, Ben Policicchiob, Egidio Brocca-Cofanob,
Claire Deleagec et. (2016). Envelope residue 375 substitutions in simian–human
immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.
Retrieved from: file:///C:/Users/Riham/Downloads/HIV%20article%2010.pdf
17- Jean-Philippe Juliena,b,c,1, Jeong Hyun Leea, Gabriel Ozorowskia, Yuanzi Huaa, Alba
Torrents de la Peñad, Steven W. de Taeyed, Travis Nieusmaa, Albert Cupoe, Anila
Yasmeene, Michael Golabeke, Pavel Pugache et.(2015). Design and structure of two
HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env
immunogens. Retrieved from:
file:///C:/Users/Riham/Downloads/HIV%20article%2011.pdf

18- S. Munir Alam, S. Moses Dennison, Baptiste Aussedatd, Yusuf Vohrad, Peter K. Parkd,
Alberto Fernéndez-Tejadad Shelley Stewart, Frederick H. Jaeger, Kara Anasti, Julie H.
Blinn, Thomas B. Kepler, Mattia Bonsignori. (2013). Recognition of synthetic
glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors.
Retrieved from: file:///C:/Users/Riham/Downloads/HIV%20article%208.pdf
19- TIMOTHY K. HARTt, RICHARD KIRSHt, HARMA ELLENSt, RAYMOND W.
SWEET?, DENNIS M. LAMBERT?, STEPHEN R. PETTEWAY, JR.?, JEFFRY
LEARY?, AND PETER J. BUGELSKI. (1990). Binding of soluble CD4 proteins to
human immunodeficiency virus type 1 and infected cells induces release of envelope
glycoprotein gp120. Retrieved From:
file:///C:/Users/Riham/Downloads/HIV%20article%209.pdf

20- James M. Kovacsa, Joseph P. Nkololac, Hanqin Penga, Ann Cheungc, James Perryc,
Caroline A. Miller, Michael S. Seaman, Dan H. Barouch, and Bing Chena. (2012). HIV-1
envelope trimer elicits more potent neutralizing antibody responses than monomeric
gp120. Retrieved From: file:///C:/Users/Riham/Downloads/HIV%20article%206.pdf
21- Saunders, C. J., McCaffrey, R. A., Zharkikh, I., Kraft, Z., Malenbaum, S. E., Burke, B.,
… Stamatatos, L. (2005, July 1). The V1, V2, and V3 Regions of the Human
Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in
an Isolate-Dependent Manner. Retrieved from
https://jvi.asm.org/content/79/14/9069#abstract-1

28

22- Huang, C.-chin, Tang, M., Zhang, M.-Y., Majeed, S., Montabana, E., Stanfield, R. L., …
Kwong, P. D. (2005, November 11). Structure of a V3-containing HIV-1 gp120 core.
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408531/
23- Landais, E., & Moore, P. L. (2018, September 5). Development of broadly neutralizing
antibodies in HIV-1 infected elite neutralizers. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125991/
24- Liu, L., Cimbro, R., Lusso, P., & Berger, E. A. (2011, December 13). Intraprotomer
masking of third variable loop (V3) epitopes by the first and second variable loops
(V1V2) within the native HIV-1 envelope glycoprotein trimer. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250183/
25- McCaffrey, R. A., Saunders, C., Hensel, M., & Stamatatos, L. (2004, April). N-linked
glycosylation of the V3 loop and the immunologically silent face of gp120 protects
human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and antigp41 antibodies. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC371088/
26- Hioe, C. E., Wrin, T., Seaman, M. S., Yu, X., Wood, B., Self, S., … Zolla-Pazner, S.
(2010, April 21). Anti-V3 monoclonal antibodies display broad neutralizing activities
against multiple HIV-1 subtypes. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858080/
27- Phillips, A. N., Cambiano, V., Nakagawa, F., Ford, D., Lundgren, J. D., RosetBahmanyar, E., … Van Effelterre, T. (2014, September 10). Potential future impact of a
partially effective HIV vaccine in a southern African setting. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/25207973
28- Susan Zolla-PaznerPing ZhongKathy ReveszBarbara VolskyConstance WilliamsPhillipe
NyambiMiroslaw K. Gorny, Zolla-Pazner, S., Zhong, P., Revesz, K., Volsky, B.,
Williams, C., … Felsövályi, K. (2004, November 19). The Cross-Clade Neutralizing
Activity of a Human Monoclonal Antibody Is Determined by the GPGR V3 Motif of
HIV Type 1. Retrieved from
https://www.liebertpub.com/doi/abs/10.1089/aid.2004.20.1254
29- Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., …
Poignard, P. (2011, September 22). Broad neutralization coverage of HIV by multiple
highly potent antibodies. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/21849977

29

30- Rubens, M., Ramamoorthy, V., Saxena, A., Shehadeh, N., & Appunni, S. (2015). HIV
Vaccine: Recent Advances, Current Roadblocks, and Future Directions. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633685/#B58
31- Zolla-Pazner, S. (2014, July 11). A critical question for HIV vaccine development: which
antibodies to induce? Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25013066

